Search Within

Thoracic Oncology

  1. "2010"
Formats
  1. Journal Article (22)
  2. Meeting Abstract (14)
Groups
  1. Department of Medicine (36)
  2. Solid Tumor Oncology Division (36)
  3. Department of Pathology and Laboratory Medicine (13)
  4. Surgery (11)
  5. GSK Faculty (9)
  6. Tow Center for Developmental Oncology (TCDO) (8)

More Groups

People
  1. Mark Kris (30)
  2. Gregory Riely (20)
  3. William Pao (10)
  4. Lee Krug (9)
  5. Valerie Rusch (9)
  6. Maria Pietanza (8)

More People

Years
  1. 2010 (36)
Publications
  1. Journal of Clinical Oncology (11)
  2. Journal of Thoracic Oncology (8)
  3. Cancer Chemotherapy and Pharmacology (2)
  4. Clinical Cancer Research (2)
  5. Modern Pathology (2)
  6. Oncology (Norwalk) (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (11)
  2. Elsevier Inc. (8)
  3. Springer (3)
  4. American Association for Cancer Research (2)
  5. C M P Medica LLC * The Oncology Group (2)
  6. Nature Research (2)

More Publishers

Results (36)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations
    Meeting Abstract

    Yeo, W.; Riely, G. J.; Yeap, B.; Lau, M. W.; Warner, J.; Bodio, K. A.; Kris, M. G.; Pao, W.; Kobayashi, S.; Costa, D. B.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Phase II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib
    Meeting Abstract

    Riely, G. J.; Janjigian, Y. Y.; Azzoli, C. G.; Pietanza, M.; Krug, L. M.; Rizvi, N. A.; Kris, M. G.; Miller, V. A.; Pao, W.; Ginsberg, M. S.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Prognostic implications of mutations in the epidermal growth factor receptor (EGFR) and KRAS among never-smokers with adenocarcinoma of the lung
    Meeting Abstract

    Paik, P. K.; Johnson, M. L.; D'Angelo, S. P.; Sima, C.; Janjigian, Y. Y.; Riely, G. J.; Kris, M. G.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Clinical course of patients (pts) with acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKI)
    Meeting Abstract

    Oxnard, G. R.; Riely, G. J.; Arcila, M. H.; Kris, M. G.; Pao, W.; Ladanyi, M.; Miller, V. A.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • EGFR mutations in men and cigarette smokers with lung adenocarcinoma
    Meeting Abstract

    Pietanza, M.; D'Angelo, S. P.; Johnson, M. L.; Paik, P. K.; Riely, G. J.; Miller, V. A.; Zakowski, M. F.; Rusch, V. W.; Ladanyi, M.; Kris, M. G.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Analysis of a panel of serum biomarkers in patients with metastatic lung cancer
    Meeting Abstract

    Lou, E.; Johnson, M. L.; Sima, C.; Gonzalez-Espinoza, R.; Kris, M. G.; Azzoli, C. G.; Fleisher, M.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Initial results of LC-MAP: An institutional program to routinely profile tumor specimens for the presence of mutations in targetable pathways in all patients with lung adenocarcinoma
    Meeting Abstract

    Kris, M. G.; Lau, C. Y.; Ang, D.; Brzostowski, E.; Riely, G. J.; Rusch, V. W.; Jhanwar, S.; Lash, A.; Zakowski, M. F.; Ladanyi, M.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinoma
    Meeting Abstract

    Johnson, M. L.; Sima, C.; Paik, P. K.; Janjigian, Y. Y.; Pao, W.; Kris, M. G.; Ladanyi, M.; Riely, G. J.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Impact of EGFR and KRAS mutations on survival in 1,000 patients with resected lung adenocarcinoma
    Meeting Abstract

    D'Angelo, S. P.; Janjigian, Y. Y.; Kris, M. G.; Pao, W.; Riely, G. J.; Marks, J.; Sima, C.; Dycoco, J.; Park, B. J.; Azzoli, C. G.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Use of PET-measured response in involved mediastinal lymph nodes to predict overall survival (OS) in non-small cell lung cancer (NSCLC) patients treated with induction therapy (IT) and surgery
    Meeting Abstract

    Barnett, S.; Plourde, G.; Zheng, J.; Pietanza, M.; Akhurst, T. J.; Downey, R. J.; Kris, M. G.; Shen, R.; Rusch, V. W.; Park, B. J.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save